Using Tumor Treating Fields for patients with pleural mesothelioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather real-world data on the effectiveness of Tumor Treating Fields (TTFields) in patients diagnosed with pleural mesothelioma who are receiving routine clinical care. Eligible patients will be those with histologically confirmed pleural mesothelioma who have no options for curative surgery and are planned to receive treatment with the NovoTTF-200T System. Participants will provide informed consent for their data to be used and processed for research purposes, allowing for a comprehensive analysis of TTFields in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years of age
* Histologically confirmed pleural mesothelioma without any option of curative resection
* Planned treatment with NovoTTF-200T System according to IFU and medical guidelines
* Life expectancy more than 3 months at day of enrollment
* Signed informed consent for use and processing of data

Exclusion Criteria:

• Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment

Where it's running

• Lungenklinik Gauting
  Gauting, Bavaria, Germany Recruiting
• University Hospital Regensburg
  Regensburg, Bavaria, Germany Recruiting
• Asklepios Klinikum Harburg
  Harburg, Free and Hanseatic City of Hamburg, Germany Recruiting
• Klinikum Bremen-Ost
  Bremen, Free Hanseatic City of Bremen, Germany Recruiting
• University Medicine Göttingen
  Göttingen, Lower Saxony, Germany Recruiting
• University Hospital Carl Gustav Carus Dresden
  Dresden, Saxony, Germany Recruiting

Study contacts

• Study coordinator: Giovanni Ceresoli
• Email: giovanni.ceresoli@mc.humanitas.it
• Phone: +392 9626717

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comprehensive multi-omics and functional profiling to fully characterize tumors

  This project tests whether detailed multi-omics and functional testing of tumor samples can better characterize high-risk blood and solid cancers for patients at participating centers.

  Recruiting at 2 sites Azienda Ospedaliero-Universitaria di Parma · Palermo, Palermo and 1 other locations · NCT07403630

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Evaluating FAPI PET for diagnosing pleural mesothelioma

  This study is testing a new type of imaging called FAPI PET/CT to see if it can better diagnose pleural mesothelioma in patients compared to standard imaging methods.

  Recruiting Phase 2 Aalborg University Hospital · Aalborg, Region North Jutland · NCT06790082

• MT027 treatment for patients with pleural malignant tumors

  This study is testing a new treatment called MT027 for patients with pleural malignant tumors to see if it's safe and how well it works after they have already received standard treatment.

  Recruiting Phase 1 Suzhou Maximum Bio-tech Co., Ltd. · Beijing · NCT06726564

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.